Form 4: Intellia Therapeutics CSO Sells Shares for Tax Obligations

Intellia Therapeutics' Chief Scientific Officer, Birgit C. Schultes, sold 8,508 shares of common stock at $9.21 per share to cover tax withholding obligations related to RSU vesting.

Summary

• Birgit C. Schultes, EVP, Chief Scientific Officer of Intellia Therapeutics, Inc. (NTLA), reported a transaction involving the company's common stock.
• On January 5, 2026, 8,508 shares of common stock were disposed of at a price of $9.21 per share.
• This transaction was a mandatory "sell-to-cover" to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) on January 1, 2026, and was not a volitional trade by the reporting person.
• Following this transaction, Ms. Schultes beneficially owns 98,533 shares of common stock.
• The reported beneficial ownership includes 925 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2025, and an additional 932 shares acquired under the same plan on December 31, 2025.

Sentiment

Score: 5

Explanation: The transaction is a mandatory "sell-to-cover" for tax obligations related to RSU vesting, which is a routine event and not indicative of management's sentiment towards the company's future performance.

Positives

• Vesting of Restricted Stock Units (RSUs) for the EVP, Chief Scientific Officer, indicates continued executive compensation and retention, aligning executive interests with company performance.

Negatives

• No direct negatives for the company are explicitly stated in this compliance filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

N/A

Industry Context

N/A

Stakeholder Impact

• Shareholders: The sale represents a minor dilution but is a standard part of executive compensation, which aims to align executive and shareholder interests. The non-volitional nature of the sale means it does not signal a lack of confidence from the executive.
• Employees: No direct impact on employees is mentioned in this filing.

Key Dates

Recommendation

This Form 4 details a routine, non-volitional "sell-to-cover" transaction by an executive to satisfy tax obligations upon RSU vesting. Such transactions are common and do not typically reflect the executive's sentiment about the company's future prospects or warrant a change in investment recommendation based solely on this filing.

Keywords

Intellia Therapeutics, NTLA, Form 4, Insider Transaction, Stock Sale, Executive Compensation, RSU Vesting, Birgit C. Schultes, Biotechnology, Gene Editing